Boston Scientific Corp.
Income Statement
| Line Item | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $9.82B | $9.05B | $8.39B | $8.07B | $7.46B | $7.07B | $6.96B | $7.62B |
| Endoscopy | $1.76B | $1.62B | $1.44B | — | — | — | — | — |
| Urology | $1.25B | $1.12B | $1.01B | — | — | — | — | — |
| Neuromodulation | $779.0M | $635.0M | $556.0M | — | — | — | — | — |
| Cardiac Rhythm Management | $1.95B | $1.89B | $1.85B | — | — | — | — | — |
| Electrophysiology | $311.0M | $278.0M | $243.0M | — | — | — | — | — |
| Interventional Cardiology | $2.59B | $2.42B | $2.28B | — | — | — | — | — |
| Peripheral Interventions | $1.19B | $1.08B | $1.01B | — | — | — | — | — |
| Watchman | — | — | — | — | — | — | — | — |
| Interventional Cardiology & Vascular Therapies | — | — | — | — | — | — | — | — |
| Interventional Oncology & Embolization | — | — | — | — | — | — | — | — |
| Specialty Pharmaceuticals/Other | — | — | — | — | — | — | — | — |
| Cost of Revenue | $2.81B | $2.59B | $2.42B | $2.17B | $2.21B | $2.17B | $2.35B | $2.66B |
| Gross Profit | $7.01B | $6.46B | $5.96B | $5.30B | $5.17B | $4.97B | $4.90B | $4.96B |
| Gross Margin | 71.4% | 71.3% | 71.1% | 65.7% | 69.3% | 70.3% | 70.4% | 65.1% |
| Operating Expenses | ||||||||
| Research & Development | — | — | — | — | — | — | — | — |
| SG&A Expense | $3.57B | $3.29B | $3.10B | $2.87B | $2.90B | $2.67B | $2.54B | $2.49B |
| Operating Income | $1.51B | $1.29B | $447.0M | $-283.0M | $-301.0M | $120.0M | $-3.87B | $904.0M |
| Operating Margin | 15.3% | 14.2% | 5.3% | -3.5% | -4.0% | 1.7% | -55.6% | 11.9% |
| Interest Expense | $241.0M | $229.0M | $233.0M | $284.0M | $216.0M | $324.0M | $261.0M | $281.0M |
| Pretax Income | $1.42B | $933.0M | $177.0M | $-650.0M | $-509.0M | $-223.0M | $-4.11B | $642.0M |
| Income Tax Expense | $-249.0M | $828.0M | $-170.0M | $-411.0M | $-390.0M | $-102.0M | $-39.0M | $201.0M |
| Net Income | $1.67B | $104.0M | $347.0M | $-239.0M | $-119.0M | $-121.0M | $-4.07B | $441.0M |
| Net Margin | 17.0% | 1.1% | 4.1% | -3.0% | -1.6% | -1.7% | -58.5% | 5.8% |
| EPS (Basic) | $1.21 | $0.08 | $0.26 | $-0.18 | $-0.09 | $-0.09 | $-2.89 | $0.29 |
| EPS (Diluted) | $1.19 | $0.08 | $0.25 | $-0.18 | $-0.09 | $-0.09 | $-2.89 | $0.29 |
| Shares Outstanding (Basic) | 1.38B | 1.37B | 1.36B | 1.34B | 1.32B | 1.34B | 1.41B | 1.51B |
| Shares Outstanding (Diluted) | 1.40B | 1.39B | 1.38B | 1.34B | 1.32B | 1.34B | 1.41B | 1.52B |
| Dividends Per Share | — | — | — | — | — | — | — | — |